This trial is testing whether a drug can help prevent a condition where the transplanted cells from a donor can attack the body's normal cells and improve transplant outcomes in patients with primary and secondary myelofibrosis.
1 Primary · 8 Secondary · Reporting Duration: At 1 and 2 years
Experimental Treatment
45 Total Participants · 1 Treatment Group
Primary Treatment: Total-Body Irradiation · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: